0.9251USD+4.89%Mkt Cap: 41.10M USDP/E: —Last update: 2026-05-26
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is che…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap41.10M USD
Enterprise Value27.48M USD
Revenue (TTM)1.49M USD
Gross Profit796.00K USD
Net Income (TTM)-11.17M USD
Revenue/Share0.0400 USD
Last Price0.9251 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.78
PEG—
EV/EBITDA-2.22
EV/Revenue18.45
P/S26.70
P/B3.53
EPS (TTM)-0.33
EPS (Forward)-0.13
52W Range
0.701030% of range1.450
52W High1.450 USD
52W Low0.7010 USD
Profitability
Gross Margin70.88%
Oper. Margin-616.16%
EBITDA Margin0.00%
Profit Margin-994.48%
ROE-205.98%
ROA-137.96%
Growth
Revenue Growth185.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.97M USD
CapEx (TTM)2.00K USD
FCF Margin-428.18%
FCF Yield-15.51%
Net Debt-12.28M USD
Net Debt/EBITDA0.99
Balance Sheet
Debt/Equity0.04
Current Ratio7.15
Quick Ratio6.58
Book Value/Sh0.2500 USD
Cash/Share0.2740 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)6.905 USD
Target Range3.000 USD – 13.50 USD
# Analysts4
Ownership
Shares Out.45.10M
Float39.90M
Insiders3.77%
Institutions19.01%
Short Interest
Short Ratio1.6d
Short % Float1.16%
Short % Out.1.12%
Shares Short505.89K
Short (prev mo.)594.80K
Technical
SMA 500.9389 (-1.5%)
SMA 2000.9990 (-7.4%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)290.97K
Avg Vol (10d)295.29K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—